S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 11.8 CHF 0.51% Market Closed
Market Cap: 125.3m CHF
Have any thoughts about
Santhera Pharmaceuticals Holding AG?
Write Note

Intrinsic Value

SANN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SANN stock under the Base Case scenario is 32.77 CHF. Compared to the current market price of 11.8 CHF, Santhera Pharmaceuticals Holding AG is Undervalued by 64%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SANN Intrinsic Value
32.77 CHF
Undervaluation 64%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation History
Santhera Pharmaceuticals Holding AG

Valuation History Unavailable

Historical valuation for SANN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
Compare SANN to

Fundamental Analysis

Santhera Pharmaceuticals Holding AG
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SANN?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Santhera Pharmaceuticals Holding AG

Provide an overview of the primary business activities
of Santhera Pharmaceuticals Holding AG.

What unique competitive advantages
does Santhera Pharmaceuticals Holding AG hold over its rivals?

What risks and challenges
does Santhera Pharmaceuticals Holding AG face in the near future?

Has there been any significant insider trading activity
in Santhera Pharmaceuticals Holding AG recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Santhera Pharmaceuticals Holding AG.

Provide P/S
for Santhera Pharmaceuticals Holding AG.

Provide P/E
for Santhera Pharmaceuticals Holding AG.

Provide P/OCF
for Santhera Pharmaceuticals Holding AG.

Provide P/FCFE
for Santhera Pharmaceuticals Holding AG.

Provide P/B
for Santhera Pharmaceuticals Holding AG.

Provide EV/S
for Santhera Pharmaceuticals Holding AG.

Provide EV/GP
for Santhera Pharmaceuticals Holding AG.

Provide EV/EBITDA
for Santhera Pharmaceuticals Holding AG.

Provide EV/EBIT
for Santhera Pharmaceuticals Holding AG.

Provide EV/OCF
for Santhera Pharmaceuticals Holding AG.

Provide EV/FCFF
for Santhera Pharmaceuticals Holding AG.

Provide EV/IC
for Santhera Pharmaceuticals Holding AG.

Show me price targets
for Santhera Pharmaceuticals Holding AG made by professional analysts.

What are the Revenue projections
for Santhera Pharmaceuticals Holding AG?

How accurate were the past Revenue estimates
for Santhera Pharmaceuticals Holding AG?

What are the Net Income projections
for Santhera Pharmaceuticals Holding AG?

How accurate were the past Net Income estimates
for Santhera Pharmaceuticals Holding AG?

What are the EPS projections
for Santhera Pharmaceuticals Holding AG?

How accurate were the past EPS estimates
for Santhera Pharmaceuticals Holding AG?

What are the EBIT projections
for Santhera Pharmaceuticals Holding AG?

How accurate were the past EBIT estimates
for Santhera Pharmaceuticals Holding AG?

Compare the revenue forecasts
for Santhera Pharmaceuticals Holding AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Santhera Pharmaceuticals Holding AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Santhera Pharmaceuticals Holding AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Santhera Pharmaceuticals Holding AG compared to its peers.

Compare the P/E ratios
of Santhera Pharmaceuticals Holding AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Santhera Pharmaceuticals Holding AG with its peers.

Analyze the financial leverage
of Santhera Pharmaceuticals Holding AG compared to its main competitors.

Show all profitability ratios
for Santhera Pharmaceuticals Holding AG.

Provide ROE
for Santhera Pharmaceuticals Holding AG.

Provide ROA
for Santhera Pharmaceuticals Holding AG.

Provide ROIC
for Santhera Pharmaceuticals Holding AG.

Provide ROCE
for Santhera Pharmaceuticals Holding AG.

Provide Gross Margin
for Santhera Pharmaceuticals Holding AG.

Provide Operating Margin
for Santhera Pharmaceuticals Holding AG.

Provide Net Margin
for Santhera Pharmaceuticals Holding AG.

Provide FCF Margin
for Santhera Pharmaceuticals Holding AG.

Show all solvency ratios
for Santhera Pharmaceuticals Holding AG.

Provide D/E Ratio
for Santhera Pharmaceuticals Holding AG.

Provide D/A Ratio
for Santhera Pharmaceuticals Holding AG.

Provide Interest Coverage Ratio
for Santhera Pharmaceuticals Holding AG.

Provide Altman Z-Score Ratio
for Santhera Pharmaceuticals Holding AG.

Provide Quick Ratio
for Santhera Pharmaceuticals Holding AG.

Provide Current Ratio
for Santhera Pharmaceuticals Holding AG.

Provide Cash Ratio
for Santhera Pharmaceuticals Holding AG.

What is the historical Revenue growth
over the last 5 years for Santhera Pharmaceuticals Holding AG?

What is the historical Net Income growth
over the last 5 years for Santhera Pharmaceuticals Holding AG?

What is the current Free Cash Flow
of Santhera Pharmaceuticals Holding AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Santhera Pharmaceuticals Holding AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Santhera Pharmaceuticals Holding AG

Current Assets 33.6m
Cash & Short-Term Investments 16.5m
Receivables 10.4m
Other Current Assets 6.7m
Non-Current Assets 74.6m
Long-Term Investments 342k
PP&E 2.8m
Intangibles 71.5m
Current Liabilities 53.1m
Accounts Payable 14.9m
Accrued Liabilities 10.2m
Other Current Liabilities 27.9m
Non-Current Liabilities 7.1m
Long-Term Debt 2.4m
Other Non-Current Liabilities 4.7m
Efficiency

Free Cash Flow Analysis
Santhera Pharmaceuticals Holding AG

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Santhera Pharmaceuticals Holding AG

Revenue
39.1m CHF
Cost of Revenue
-15.5m CHF
Gross Profit
23.6m CHF
Operating Expenses
-56.7m CHF
Operating Income
-33.2m CHF
Other Expenses
-8.8m CHF
Net Income
-42m CHF
Fundamental Scores

SANN Profitability Score
Profitability Due Diligence

Santhera Pharmaceuticals Holding AG's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional Revenue Growth Forecast
ROIC is Increasing
Negative 1-Year Revenue Growth
26/100
Profitability
Score

Santhera Pharmaceuticals Holding AG's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

SANN Solvency Score
Solvency Due Diligence

Santhera Pharmaceuticals Holding AG's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
41/100
Solvency
Score

Santhera Pharmaceuticals Holding AG's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SANN Price Targets Summary
Santhera Pharmaceuticals Holding AG

Wall Street analysts forecast SANN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

Lowest
Price Target
30.3 CHF
157% Upside
Average
Price Target
30.6 CHF
159% Upside
Highest
Price Target
31.5 CHF
167% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Santhera Pharmaceuticals Holding AG
does not pay dividends
Shareholder Yield

Current shareholder yield for SANN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SANN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SANN stock?

The intrinsic value of one SANN stock under the Base Case scenario is 32.77 CHF.

Is SANN stock undervalued or overvalued?

Compared to the current market price of 11.8 CHF, Santhera Pharmaceuticals Holding AG is Undervalued by 64%.

Back to Top